Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein-Barr Virus or adenovirus after allogeneic stem cell transplantation

Klinische Padiatrie

Volumn 225, Issue 3, 2013, Pages 164-169

  Feucht, J ^a   Joachim, L ^a   Lang, P ^a   Feuchtinger, Tobias ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

allogeneic stem cell transplantation; T cell transfer; virus infection

Indexed keywords

ANTIVIRUS AGENT;

ADENOVIRUS; ADENOVIRUS INFECTION; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN SPECIFICITY; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNOSTIMULATION; INFECTION CONTROL; INFECTION RISK; LYMPHOCYTE TRANSFER; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS REACTIVATION;

ADENOVIRIDAE INFECTIONS; ADOPTIVE TRANSFER; CHILD; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN-BARR VIRUS INFECTIONS; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; OPPORTUNISTIC INFECTIONS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84878392125     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0033-1333749     Document Type: Review

References (48)

1. Boeckh M., Nichols W. G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood: 2004; 103 2003 2008 (Pubitemid 38326213)
2. Einsele H., Hebart H., Kauffmann-Schneider C. et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant: 2000; 25 757 763 (Pubitemid 30189517)
3. Schuster F. R., Simon A., Laws H. J. et al. Viral infections in pediatric cancer patients. Klin Padiatr: 2005; 217 01 S67 S84 (Pubitemid 41746055)
4. Mohty M., Jacot W., Faucher C. et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK: 2003; 17 2168 2177 (Pubitemid 37428382)
5. Kapp M., Tan S. M., Einsele H. et al. Adoptive immunotherapy of HCMV infection. Cytotherapy: 2007; 9 699 711 (Pubitemid 350237080)
6. Koehl U., Dirkwinkel E., Koenig M. et al. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group. Klin Padiatr: 2008; 220 348 352
7. Flomenberg P., Babbitt J., Drobyski W. R. et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis: 1994; 169 775 781 (Pubitemid 24102109)
8. Shields A. F., Hackman R. C., Fife K. H. et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med: 1985; 312 529 533 (Pubitemid 15174147)
9. Feuchtinger T., Lang P., Handgretinger R. Adenovirus infection after allogeneic stem cell transplantation. Leuk Lymphoma: 2007; 48 244 255 (Pubitemid 46994874)
10. La Rosa A. M., Champlin R. E., Mirza N. et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis: 2001; 32 871 876 (Pubitemid 32524820)
11. Feuchtinger T., Richard C., Pfeiffer M. et al. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update. Klin Padiatr: 2005; 217 339 344 (Pubitemid 41746116)
12. Echavarria M., Forman M., van Tol M. J. et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet: 2001; 358 384 385 (Pubitemid 32739102)
13. Lion T., Baumgartinger R., Watzinger F. et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood: 2003; 102 1114 1120 (Pubitemid 36917814)
14. Ocheni S., Kroeger N., Zabelina T. et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant: 2008; 42 181 186
15. Handgretinger R., Lang P., Schumm M. et al. Immunological aspects of haploidentical stem cell transplantation in children. Ann N Y Acad Sci: 2001; 938 340 357; discussion 57-58
16. Chiusolo P., Metafuni E., Cattani P. et al. Prospective Evaluation of Epstein-Barr Virus Reactivation After Stem Cell Transplantation: Association with Monoclonal Gammopathy. J Clin Immunol: 2010; 30 894 902
17. Tran H., Nourse J., Hall S. et al. Immunodeficiency-associated lymphomas. Blood Rev: 2008; 22 261 281
18. Buyck H. C., Ball S., Junagade P. et al. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant: 2009; 43 813 816
19. Bahceci E., Epperson D., Douek D. C. et al. Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected by graft-versus-host disease or mixed chimaerism. British journal of haematology: 2003; 122 934 943 (Pubitemid 37174614)
20. Lewin S. R., Heller G., Zhang L. et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood: 2002; 100 2235 2242 (Pubitemid 35001261)
21. Wagner H. J., Cheng Y. C., Huls M. H. et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood: 2004; 103 3979 3981 (Pubitemid 38596322)
22. Meij P., van Esser J. W., Niesters H. G. et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood: 2003; 101 4290 4297 (Pubitemid 36857791)
23. van Esser J. W., van der Holt B., Meijer E. et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood: 2001; 98 972 978
24. Heslop H. E. How I treat EBV lymphoproliferation. Blood: 2009; 114 4002 4008
25. Heslop H. E., Li C., Krance R. A. et al. Epstein-Barr infection after bone marrow transplantation. Blood: 1994; 83 1706 1708 (Pubitemid 24081590)
26. Leen A. M., Tripic T., Rooney C. M. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther: 2010; 10 337 351
27. Walter E. A., Greenberg P. D., Gilbert M. J. et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med: 1995; 333 1038 1044
28. Einsele H., Roosnek E., Rufer N. et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood: 2002; 99 3916 3922 (Pubitemid 35332029)
29. Peggs K. S., Verfuerth S., Pizzey A. et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet: 2003; 362 1375 1377 (Pubitemid 37338339)
30. Micklethwaite K. P., Clancy L., Sandher U. et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood: 2008; 112 3974 3981
31. Rooney C. M., Smith C. A., Ng C. Y. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet: 1995; 345 9 13
32. Gattinoni L., Klebanoff C. A., Palmer D. C. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest: 2005; 115 1616 1626 (Pubitemid 40814670)
33. Feuchtinger T., Opherk K., Bethge W. A. et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood: 2010; 116 4360 4367
34. Feuchtinger T., Matthes-Martin S., Richard C. et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. British journal of haematology: 2006; 134 64 76 (Pubitemid 43830030)
35. Cobbold M., Khan N., Pourgheysari B. et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med: 2005; 202 379 386 (Pubitemid 41126955)
36. Schmitt A., Tonn T., Busch D. H. et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion: 2011; 51 591 599
37. Uhlin M., Gertow J., Uzunel M. et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America: 2012; 55 1064 1073
38. Rooney C. M., Smith C. A., Ng C. Y. et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood: 1998; 92 1549 1555 (Pubitemid 28406858)
39. Einsele H., Rauser G., Grigoleit U. et al. Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide. Cytotherapy: 2002; 4 49 54 (Pubitemid 34752391)
40. Leen A. M., Myers G. D., Sili U. et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med: 2006; 12 1160 1166 (Pubitemid 44527351)
41. Riddell S. R., Watanabe K. S., Goodrich J. M. et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science: 1992; 257 238 241
42. Papadopoulos E. B., Ladanyi M., Emanuel D. et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med: 1994; 330 1185 1191 (Pubitemid 24121987)
43. Heslop H. E., Slobod K. S., Pule M. A. et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood: 2010; 115 925 935
44. Haque T., Wilkie G. M., Taylor C. et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet: 2002; 360 436 442 (Pubitemid 34880139)
45. Haque T., Wilkie G. M., Jones M. M. et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood: 2007; 110 1123 1131 (Pubitemid 47281407)
46. Icheva V., Kayser S., Wolff D. et al. Adoptive Transfer of Epstein-Barr Virus (EBV) Nuclear Antigen 1-Specific T Cells As Treatment for EBV Reactivation and Lymphoproliferative Disorders After Allogeneic Stem-Cell Transplantation. J Clin Oncol: 2013; 31 39 48
47. Feuchtinger T., Richard C., Pfeiffer M. et al. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: An update. Klinische Padiatr: 2005; 217 339 344 (Pubitemid 41746116)
48. Leen A. M., Christin A., Myers G. D. et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood: 2009; 114 4283 4292